Search Results for "Boehringer Ingelheim Study With B1 10773"
Original Source: Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients with Typ 2 Diabetes Mellitus with insufficient glycaemic control.
Matching Channels
Boehringer Ingelheim is a global pharmaceutical company with annual sales of over $16 billion, making it the 10th largest pharmaceutical company in the world based on sales. With bases in 47 c...
SERAPHIN - STUDY WITH ENDOTHELIN RECEPTOR ANTAGONIST IN PULMONARY ARTERIAL HYPERTENSION TO IMPROVE CLINICAL OUTCOME. SERAPHIN (Study with an Endothelin Rece...
The pharmaceutical industry is massive, both in range of products and in financial values. These are the top 200 drugs (ranked in descending order according to total sales in 20010, $), and the co...
Connecticut, a state in the north-east corner of the US is a hub for biotechnology companies. There are over 100 high-quality companies with global markets based in Connecticut. In 2004, Connectic...
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyle...
Matching News
BaroFold and Boehringer Ingelheim announce strategic alliance for protein refolding technology
BaroFold and Boehringer Ingelheim have entered into a non-exclusive technology and commercial license option agreement.Boehringer Ingelheim will acquire a laboratory-scale reactor of BaroFold’s Pres...
Ensemble, Boehringer Ingelheim collaborate on macrocycle drug candidates
Ensemble Therapeutics of Cambridge, Mass., has initiated a research collaboration with Germany-based Boehringer Ingelheim to discover drug candidates of a novel class of small molecule drugs, called m...
Boehringer Ingelheim announces changes to Board of Managing Directors
The Shareholders of Boehringer Ingelheim have appointed Dr Joachim Hasenmaier to Boehringer Ingelheim’s Board of Managing Directors. The 52-year old will take over responsibility for the new Consume...
Boehringer Ingelheim acquires FX125L and somatotaxin portfolio rights
Boehringer Ingelheim and Funxional Therapeutics announced an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics’ FX125L compound and somatotaxin...
Boehringer Ingelheim acquires Funxional Therapeutics inflammation portfolio
Boehringer Ingelheim and Funxional Therapeutics, have formed an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics’ FX125L compound and somatotaxin p...
Ensemble Therapeutics and Boehringer Ingelheim ink $186 milliion macrocycle drug pact
Ensemble Therapeutics announced the initiation of a research collaboration with Boehringer Ingelheim to discover drug candidates of a novel class of small molecule drugs, called macrocycles, against s...
Boehringer Ingelheim starts biosimilar rituximab trial
Germany-based Boehringer Ingelheim Pharmaceuticals (Boehringer Ingelheim) is starting a Phase III trial for a biosimilar version of rituximab.
Boehringer Ingelheim completes biosimilar adalimumab trial
Biopharmaceutical specialist Boehringer Ingelheim Pharmaceuticals (Boehringer Ingelheim) has completed its phase I trial for a biosimilar version of adalimumab.
Matching PubMed Articles
Lessons from 54 years of pharmaceutical research.
Regulatory aspects of devices.
A novel series of pyrazole sEH inhibitors is reported. Lead optimization efforts to replace the aniline core are also described. In particular, 2-pyridine, 3-pyridine and pyridazine analogs are potent...
Efficient Synthesis of a Small Molecule, Nonpeptide Inhibitor of LFA-1.
A three-stage process for the synthesis of LFA-1 inhibitor 1 from amine 4 with an overall yield of 65% is described. The key stage involves a Ph(3)PCl(2)-induced dehydration/cyclization of urea 6 foll...
Direct titanium-mediated conversion of ketones into enamides with ammonia and acetic anhydride.
A one-step conversion of ketones into N-acetyl enamides was developed. The process employs safe and inexpensive reagents, proceeds under mild conditions, and tolerates diverse functional groups. The a...
